Bone Biologics (NASDAQ:BBLG) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Bone Biologics (NASDAQ:BBLG) from a sell rating to a hold rating in a report released on Sunday.

Bone Biologics Stock Up 12.7%

Bone Biologics stock opened at $2.40 on Friday. The business’s fifty day moving average is $2.38 and its 200 day moving average is $3.72. Bone Biologics has a one year low of $1.95 and a one year high of $16.12.

Bone Biologics (NASDAQ:BBLG) last announced its earnings results on Thursday, August 14th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.75). As a group, research analysts anticipate that Bone Biologics will post -5 EPS for the current year.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.